The conversation discusses using verteporfin for hair regrowth and minimizing scarring after hair transplants. Some individuals plan to self-administer verteporfin, potentially in combination with microneedling, as an alternative to hair transplants.
A user has been using minoxidil without noticing improvements and is considering adding tretinoin gel to their regimen before trying RU58841. They seek advice on how to mix and apply tretinoin with minoxidil, including concentration and application frequency.
The user is seeking advice on adding CB 03-01 to their hair loss treatment, which includes RU58841, Fluridil, Minoxidil, and Pantostin, but cannot use finasteride.
Minoxidil 5% combined with 0.01% tretinoin may be as effective as using minoxidil twice daily. Users discuss switching to oral minoxidil for consistency, with concerns about side effects.
Red light therapy has shown promising results in hair regrowth for the user, who avoids minoxidil and finasteride due to side effects. The user follows a healthy lifestyle with diet, exercise, and sauna use, and will continue monitoring the therapy's effectiveness.
The conversation is about whether it's safe to use minoxidil with a mix of stemoxydine, RU58841, alfatradiol, and tretinoin at the same time for hair loss treatment. Concerns were raised about the absorption and effectiveness when these treatments are applied together.
Regenera Activa and exosome therapy are discussed for hair loss treatment, focusing on their effectiveness for regrowth, thickening, or reducing shedding. Users are seeking experiences and results from these treatments.
The conversation discusses the completion of a Phase II trial recruitment for Breezula (CB-03-01), a potential treatment for androgenic alopecia. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.
Minoxidil is more effective when combined with retinoic acid, such as tretinoin or tazarotene, enhancing hair growth. Some users experience significant regrowth, while others see minimal effects or side effects.